Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: MARK C. who wrote (5112)	1/4/1999 7:19:00 PM
From: Dave	Respond to of 90042

Mark, I agree completely. In fact, I was on a conference call today for Searle and celecoxib. They gave out pricing info, clinical data, etc. About 75% of the medical education that I produce is on chronic pain and arthritis, so I enjoy and am familiar with that area. I do think, however, that Searle will find ways to get the word out regarding the safety of their COX-2 regardless of the labelling (In fact, that's a big part of what our company does). All I heard on the CC today was "safety, safety, safety" and they were aggressive in addressing the labelling issue up front. They certainly aren't going to sit back and take it. That combined with PFE's sales force and being first to the market aren't going to make it easy for MRK. FWIW, Dave